GeneOne Life Science, Inc.

KOSE:A011000 Stock Report

Market Cap: ₩159.1b

GeneOne Life Science Past Earnings Performance

Past criteria checks 0/6

GeneOne Life Science's earnings have been declining at an average annual rate of -44.2%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been declining at an average rate of 0.6% per year.

Key information

-44.2%

Earnings growth rate

-34.0%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-0.6%
Return on equity-82.3%
Net Margin-191.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

The Market Doesn't Like What It Sees From GeneOne Life Science, Inc.'s (KRX:011000) Revenues Yet As Shares Tumble 39%

Sep 09
The Market Doesn't Like What It Sees From GeneOne Life Science, Inc.'s (KRX:011000) Revenues Yet As Shares Tumble 39%

Is GeneOne Life Science (KRX:011000) Using Too Much Debt?

Aug 31
Is GeneOne Life Science (KRX:011000) Using Too Much Debt?

Why Investors Shouldn't Be Surprised By GeneOne Life Science, Inc.'s (KRX:011000) Low P/S

Jul 26
Why Investors Shouldn't Be Surprised By GeneOne Life Science, Inc.'s (KRX:011000) Low P/S

Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?

Mar 20
Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?

GeneOne Life Science (KRX:011000) Has Rewarded Shareholders With An Exceptional 855% Total Return On Their Investment

Jan 10
GeneOne Life Science (KRX:011000) Has Rewarded Shareholders With An Exceptional 855% Total Return On Their Investment

Revenue & Expenses Breakdown

How GeneOne Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A011000 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2437,969-72,69122,7116,115
30 Jun 2440,802-73,64524,4067,076
31 Mar 2439,841-74,03723,9995,501
31 Dec 2340,203-77,76825,7827,043
30 Sep 2337,294-52,61728,9828,554
30 Jun 2338,116-48,96428,3978,743
31 Mar 2344,176-46,74033,51812,132
31 Dec 2248,718-38,15032,27912,147
30 Sep 2249,074-25,77228,61312,736
30 Jun 2243,041-23,36928,30013,458
31 Mar 2241,443-18,68025,77811,685
31 Dec 2138,700-15,88821,70211,441
30 Sep 2140,498-23,16022,78610,377
30 Jun 2144,780-21,00720,9879,761
31 Mar 2142,305-18,35518,9099,217
31 Dec 2041,503-18,64819,5478,396
30 Sep 2041,938-11,89016,7796,873
30 Jun 2042,539-8,93914,9886,448
31 Mar 2042,244-9,28214,8335,454
31 Dec 1941,241-7,61913,5005,874
30 Sep 1938,578-7,72513,5565,938
30 Jun 1935,856-10,23315,5884,380
31 Mar 1934,037-9,34418,1504,507
31 Dec 1834,293-11,89818,4415,661
30 Sep 1830,802-16,19820,7207,454
30 Jun 1829,802-16,87222,0287,454
31 Mar 1828,147-21,72722,3116,815
31 Dec 1727,171-23,73021,1418,398
30 Sep 1729,849-21,06819,7066,787
30 Jun 1729,449-22,16719,4926,787
31 Mar 1730,785-19,40117,4736,757
31 Dec 1631,371-15,59917,0433,931
30 Sep 1629,013-11,43514,4382,567
30 Jun 1629,151-3,22711,5052,567
31 Mar 1629,4091,0318,8991,826
31 Dec 1528,3651,4149,206831
30 Sep 1526,279-2,0508,969784
30 Jun 1524,893-6,5578,926784
31 Mar 1523,652-6,9777,864816
31 Dec 1424,625-6,4928,141759
30 Sep 1427,367-3,1797,3562,569
30 Jun 1425,343-3,9936,9972,569
31 Mar 1423,671-5,4736,9742,420
31 Dec 1320,657-8,3636,4462,392

Quality Earnings: A011000 is currently unprofitable.

Growing Profit Margin: A011000 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A011000 is unprofitable, and losses have increased over the past 5 years at a rate of 44.2% per year.

Accelerating Growth: Unable to compare A011000's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A011000 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A011000 has a negative Return on Equity (-82.34%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 12:02
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GeneOne Life Science, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Reni BenjaminRodman & Renshaw, LLC